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PreviewsEBV-infected B cells and decreased
humoral response, may derive from the
inability of SAP-deficient immune cells to
form stable interactions. Because NKT
cell development requires thymocyte-
thymocyte interactions, it would be inter-
esting to confirm that SAP deficiency in
NKT cell development destabilizes thymo-
cyte-thymocyte contacts.
Imaging studies of the immunological
synapse (IS) by Zhao et al. (2012) and
Kageyama et al. (2012) can potentially
provide a mechanism for how SAP defi-
ciency may lead to decreased conjugate
stability. Both studies showed that
Ly108 was recruited to the center of the
IS of T cells conjugated to B cells. In the
presence of SAP, SHP-1 was excluded
from this central region. In contrast, in
Sh2d1a/ T cells, SHP-1 was present
throughout the entire synapse. This
affected the localization of proximal
signaling events, such as Lck phosphory-
lation at the IS (Zhao et al., 2012). It is
well known that localized signaling at the
IS is critical for optimal downstream
events such as cytoskeletal reorganiza-
tion, polarization, and adhesion to the
target cell. Therefore, local inhibition of
signaling pathways by SHP-1 recruitment
to the IS, as well as the absence of local
positive signaling through SAP, can
explain why SAP-deficient T cells cannot form stable conjugates. Indeed, in
the case of CD8+ T cells, SAP deficiency
was associated with defective cyto-
skeleton reorganization (decreased clear-
ance of the actin from the central region),
leading to impaired T cell polarity (Zhao
et al., 2012).
In summary, three papers in the current
issue of Immunity show that SAP has
a unique signaling mechanism that modu-
lates both positive and negative signaling
pathways through SLAM receptors (Fig-
ure 1). In the presence of SAP, this allows
for the engagement of SLAM family mem-
bers to have a steep amplifying effect on
T, NKT, and NK cell activation, linking
cell-cell adhesion with the signaling
machinery. This forward feedback loop
induced by SLAM family receptor adhe-
sion could then enhance inside-out sig-
naling by integrins, further enhancing
conjugate formation, allowing for addi-
tional SLAM receptor engagement. Im-
paired contacts between cells can explain
most of the immune defects observed in
SAP-deficient mice and XLP1 patients.
Further studies will be required to confirm
that SAP deficiency also impairs lym-
phocyte interactions in XLP1 patients
and to assess the relative contribution of
SAP-regulated activating and inhibitory
pathways through SLAM receptors in
human immune cells.ImmunityREFERENCES
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Interleukin 27 (IL-27) regulates immune responses, including T helper 17 (Th17) cell activity. In this issue
of Immunity, Hirahara et al. (2012) demonstrate that IL-27 suppresses Th17 cells in trans through induction
of the inhibitory ligand PD-L1 on bystander T cells.The mammalian immune system utilizes
an arsenal of diverse and powerful
effector mechanisms to deal with a wide
variety of pathogens. Without proper
control, these mechanisms can not onlykill bacteria and viruses, but also inflict
serious damage, including death, to the
host. It is therefore of vital importance
that any given immune response is care-
fully balanced in a way that ensures bothpathogen clearance as well as survival
of the host. Negative regulation of the
immune system is a field of intense re-
search, not least because it holds great
therapeutic potential: various forms of36, June 29, 2012 ª2012 Elsevier Inc. 901
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Figure 1. Schematic Representation IL-27-Dependent Th17 Cell Suppression
Cognate T cells recognize antigen presented by APC and will clonally expand. Bystander T cells do not
recognize antigen and will not expand but will still outnumber cognate T cells.
(A) Direct suppression elicited by binding of IL-27 to its receptor on the developing Th17 cell is a STAT1-
dependent effect.
(B) Indirect effect discovered by Hirahara et al. (2012) involves STAT1-dependent upregulation of PD-L1
on bystander T cells, which then signal for Th17 cell suppression through the PD-1 receptor expressed on
the cognate T cell.
APC, antigen-presenting cell; 27, interleukin-27; Th17, T helper cell type 17; STAT1, signal transducer and
activator of transcription 1; PD-1, programmed death-1; PD-L1, PD-1 ligand 1.
Immunity
Previewsautoimmune, inflammatory, and allergic
disease represent failures of negative
immune regulation; conversely, immune
responses appear to be inappropriately
suppressed in the context of chronic viral
infection and cancer.
Interleukin-27 (IL-27) is an antigen-pre-
senting cell (APC)-derived heterodimeric
cytokine consisting of p28 and EBI3
subunits,which signals througha receptor
expressed on virtually all immune cells.
Although IL-27 can promote inflammation
in some in vivo models, its predominant
in vivo role appears to be in restraining
Th1, Th2, and Th17 cell-driven immune
responses. This immunoregulatory func-
tion of IL-27 is illustrated bymice deficient
in the IL-27 receptor alpha chain (IL-
27Ra), which suffer from immune patho-
logy but not compromised pathogen
clearance in the context of a number
of Th1 and Th2 cell-dependent infec-
tious agents (Batten and Ghilardi, 2007;
Stumhofer and Hunter, 2008). Further-
more, Il27ra/mice display exacerbated
susceptibility to disease in the Th17 cell-
driven experimental autoimmune enceph-902 Immunity 36, June 29, 2012 ª2012 Elsevalomyelitis (EAE) model (Batten et al.,
2006; Stumhofer et al., 2006).
Most of the anti-inflammatory functions
of Il27ra/mice rely on signal transducer
and activator of transcription-1 (STAT-1)
activation but are independent of its
capacity to elaborate production of inter-
feron-g (IFN-g). Yet the precise mecha-
nism by which IL-27 constrains immune
responses in vivo has remained elusive.
In this issue of Immunity, Hirahara et al.
(2012) illuminate a previously unappreci-
ated mechanism of action of IL-27, show-
ing that it can suppress Th17 cell differen-
tiation in trans through STAT-1-mediated
induction of PD-L1 on bystander, noncog-
nate T cells (Figure 1).
Hirahara et al. (2012) used an ex-
perimental system in which naive T cells
were stimulated with recombinant IL-27
(without TCR ligation) and then washed.
Their effect on the activation and cytokine
production of admixed T cells was then
assessed. In such a system, IL-27-primed
T cells inhibited Th17 cell but not Th1
cell differentiation in trans. Remarkably,
IL-27-primed T cells conferred substantialier Inc.protection against EAE when cotrans-
ferred together with 2D2 transgenic
T cells into naive recipients prior to myelin
oligodendrocyte glycoprotein (MOG) im-
munization. Again, this effect involved
suppression of IL-17 (but not IFN-g)
production by the MOG-specific 2D2
T cells. Antigen specificity or even antigen
priming of the IL-27-primed T cells was
not required, suggesting that nonspecific
bystander T cells can limit Th17 cell differ-
entiation of antigen-specific effector cells
in trans.
To determine the mechanistic under-
pinnings of this effect of IL-27, the authors
profiled IL-27-induced gene expression in
T cells by microarray. This experiment led
to the identification of a number of IL-27-
induced genes and among the highest
ranking was programmed death ligand 1
(PD-L1, also known as B7-H1 or CD274).
PD-L1 and PD-L2 (B7-DC; CD273) are
members of the B7 family of costimulatory
ligands that bind to the inhibitory receptor
programmed death-1 (PD-1), which is ex-
pressed on T cells after activation. It is
well understood that signals received by
the T cell through PD-1 suppress activa-
tion after T cell receptor (TCR) signaling
through inhibition of PI3K activity, block-
ing T cell proliferation and inhibiting cyto-
kine production. Expression of PD-L1 and
PD-L2 in tissues is crucial for peripheral
tolerance, as is impressively illustrated by
mice deficient in PD-1, which suffer from
spontaneous autoimmunity in susceptible
genetic strains and from exacerbated
pathology in T cell-mediated autoimmune
disease models (Fife and Pauken, 2011).
Subsequent validation experiments by
Hirahara et al. (2012) included antibody-
mediated blockade or genetic deletion of
PD-L1 signaling, both of which neutral-
ized the ability of IL-27-primed cells to
execute Th17 cell suppression in trans.
Furthermore, recombinant PD-L1 mim-
icked the effect of IL-27-primed T cells.
Together, these results suggest that
PD-L1 is both necessary and sufficient
for Th17 cell suppression by bystander
T cells in trans.
Consistent with earlier observations
that STAT-1 can induce PD-L1 expression
in T cells (Loke and Allison, 2003), IL-27
was also found to act through STAT-1 in
this context. Furthermore, other STAT-1-
activating cytokines, such as interferons
(IFN) a, b, and g, also induced PD-L1 but
did so more broadly than IL-27, the effect
Immunity
Previewsof which was limited to T cells. This
apparent specificity is puzzling, because
it is well documented that B and myeloid
cells are fully capable of responding to
IL-27. It is therefore suggested that mech-
anisms exist to modulate the capacity
of IL-27 to induce PD-L1 in a cell type-
specific fashion.
An important implication of this study is
that noncognate bystander CD4+ T cells
can drastically influence the differentia-
tion of the antigen-specific response.
This has potentially wide reaching impli-
cations for howwe understand the control
of T helper cell activation and differentia-
tion. Presumably both cognate and non-
cognate T cells are subject to IL-27 sig-
nals under inflammatory conditions. The
authors argue that because of the over-
whelming ratio of naive:antigen-specific
CD4+ T cells, the in trans effects are likely
to be important. However, proving the
relevance of the IL-27-STAT-1-PD-L1
axis definitively in a physiological context
is a formidable challenge. We must not
forget that PD-L1 expression is potently
induced by TCR ligation already (Yama-
zaki et al., 2002), and, as the authors
and previous literature show, by STAT-1-
inducing cytokines other than IL-27.
Furthermore, IL-27 can directly suppress
Th17 cell differentiation in the context of
TCR ligation, and therefore this effect is
probably PD-L1 independent (Batten
et al., 2006). Although Hirahara et al.
(2012) relied heavily on ex vivo-manipu-
lated T cells to allow for careful dissection
of the mechanism, they nevertheless
took a first step toward addressing this
problem by interrogating PD-L1 expres-
sion in mice deficient for the Ebi3 subunit
of IL-27. Indeed, T cells in Ebi3/ mice
failed to express PD-L1 upon infection
with T. gondii. Although genetic dele-
tion experiments abrogate all effects of
IL-27, including direct ones, these data
suggest that the IL-27-PD-L1 axis may
indeed be physiologically important.
More sophisticated genetic models andthe use of radiation chimeras will be re-
quired to unambiguously define the phys-
iologic importance of IL-27-elicited and
PD-L1-mediated in trans suppression
in vivo.
Beyond IL-27, Hirahara et al. (2012)’s
data may also prompt mechanistic stud-
ies on IL-35, a recently described cyto-
kine that is closely related to IL-27 and
shares the EBI3 subunit. A body of litera-
ture exists suggesting that stimulation of
T cells with IL-35 turns them into suppres-
sive iTr35 cells (Belkaid and Chen, 2010).
The mechanism by which this happens
has not been fully elucidated, and the re-
ported in vivo data bear striking resem-
blance to Hirahara et al. (2012)’s results.
Given IL-35’s close relationship to IL-27,
as well as its capacity to activate
STAT-1, PD-L1 now has to be considered
a prime suspect to mediate the effects of
IL-35.
IL-27Ra deficiency results in exacer-
bated Th1, Th2, and Th17 cell responses
in vivo; on the other hand, in trans
suppression by the IL-27-STAT-1-PD-L1
axis was limited to Th17 cell responses
and did not affect IFN-g production at
all. It thus appears that the current study
cannot explain why Th1 cell responses
are exacerbated in Il27ra/ mice, and
Th2 cell responses were not studied.
However, the focus of the present study
was on naive cells differentiating into an
effector phenotype, which reflects only
the beginning of an immune response. It
is still possible that the immune pathology
and exacerbated production of IFN-g
seen in Il27ra/ mice infected with
T. gondii is due to the abrogation of PD-
L1 expression at a later stage during the
disease progression, especially because
the pathology does not manifest until
several days postinfection (Stumhofer
and Hunter, 2008). This hypothesis can
now be tested.
Certainly, the IL-27-STAT-1-PD-L1 axis
of immune suppression will not dominate
under all circumstances. After all, IL-27Immunityis known to be pathogenic rather than
protective in murine models of lupus,
proteoglycan-induced arthritis, and trans-
fer colitis (Wojno and Hunter, 2012).
These seemingly contradictory observa-
tions are easily reconciled by the notion
that the net outcome of any given in vivo
situation always reflects the sum of all
activating and inhibitory immune mecha-
nisms. With their elegant series of experi-
ments, Hirahara et al. (2012) uncovered a
mechanism by which IL-27 can suppress
T cell responses through noncognate,
bystander T cells. Undoubtedly, this
work will prompt many follow-up studies
to determine whether and to what extent
this mechanism actually plays in the
context of various immune challenges
and diseases.REFERENCES
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